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Abstract
Multifocal breast cancer (MFBC), defined as multiple synchronous unilateral lesions of invasive breast cancer, is
relatively frequent and has been associated with more aggressive features than unifocal cancer. Here, we aimed
to investigate the genomic heterogeneity between MFBC lesions sharing similar histopathological parameters.
Characterization of different lesions from 36 patients with ductal MFBC involved the identification of non-silent
coding mutations in 360 protein-coding genes (171 tumour and 36 matched normal samples). We selected only
patients with lesions presenting the same grade, ER, and HER2 status. Mutations were classified as ‘oncogenic’ in
the case of recurrent substitutions reported in COSMIC or truncating mutations affecting tumour suppressor genes.
All mutations identified in a given patient were further interrogated in all samples from that patient through deep
resequencing using an orthogonal platform. Whole-genome rearrangement screen was further conducted in 8/36
patients. Twenty-four patients (67%) had substitutions/indels shared by all their lesions, of which 11 carried the
same mutations in all lesions, and 13 had lesions with both common and private mutations. Three-quarters of
those 24 patients shared oncogenic variants. The remaining 12 patients (33%) did not share any substitution/indels,
with inter-lesion heterogeneity observed for oncogenic mutation(s) in genes such as PIK3CA, TP53, GATA3, and
PTEN. Genomically heterogeneous lesions tended to be further apart in the mammary gland than homogeneous
lesions. Genome-wide analyses of a limited number of patients identified a common somatic background in all
studied MFBCs, including those with no mutation in common between the lesions. To conclude, as the number of
molecular targeted therapies increases and trials driven by genomic screening are ongoing, our findings highlight
the presence of genomic inter-lesion heterogeneity in one-third, despite similar pathological features. This implies
that deeper molecular characterization of all MFBC lesions is warranted for the adequate management of those
cancers.
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Introduction
Multifocal or multicentric breast cancers are tradition-
ally defined by the presence of two or more neoplastic
lesions within a single breast quadrant or within differ-
ent quadrants of the same breast, respectively [1]. Since
these definitions do not follow any internal anatomi-
cal boundary, here we use the term multifocal breast
cancer (MFBC) to denote any ipsilateral, synchronous
tumours presenting with separate invasive lesions. The
two largest studies so far investigating the incidence
of MFBC reported multifocality in 21% and 24% of
patients, respectively [2,3]. No differences betweenmul-
tifocal and unifocal breast cancers have been reported in
the distribution of molecular subtypes defined by oestro-
gen receptor (ER), progesterone receptor (PR), HER2,
and the basal-like CK5/6, CK14, and EGFR markers
[4], suggesting that multifocality is not enriched in a
certainmolecular subtype.MFBC has instead been asso-
ciated with a potentially worse clinical outcome and
with increased axillary nodal involvement than unifocal
tumours in most but not all publications [3,5–13].
Based on the rationale that lesions with similar his-
tology and grade are expected to be biologically simi-
lar, the College of American Pathologists recommends
further characterizing all MFBC foci only when histol-
ogy and grade differ from one another [14]. However,
recent studies question this recommendation because
of well-documented intra-patient, inter-lesion discor-
dances in ER and HER2 expression (up to 4.4% and
10% discrepancy, respectively) [15–17]. We therefore
aimed to go a step further and assessed the potential
genomic differences between ductal MFBC lesions with
concordant histological grade, ER, and HER2 status,
which represent the majority of MFBCs. To this end, we
sequenced multiple lesions from a cohort of 36 patients
with MFBC using a panel of 360 cancer-related genes
and validated this analysis by ultra-deep resequencing
using an orthogonal sequencing platform. For a subset
of patients, we further characterized genome-wide struc-
tural variations to interrogate the phylogenetic relation-
ship between the various lesions.
Materials and methods
Patient selection
Patients were retrospectively selected on the basis of
the following criteria: (1) documented MFBC, defined
in the pathology report as the presence of multiple
synchronous ipsilateral invasive lesions in the surgical
specimen separated by benign breast tissue; (2) ductal
histology; (3) tumour cellularity greater than 40%; (4)
availability of two or more MFBC lesions, from which
a minimum amount of 700 ng of double-stranded DNA
(dsDNA) could be extracted; (5) similar histological
grade, ER, and HER2 status following central pathology
review of the different lesions of the same patient; (6) no
neo-adjuvant treatment; and (7) availability of germline
DNA, derived from whole blood or a tumour-free
axillary lymph node.
All 36 patients were diagnosed and operated on at
Institut Jules Bordet or Ospedale Morgagni–Pierantoni
(Forli, Italy) between 2000 and 2013. Eight of the
36 patients were selected for a whole-genome rear-
rangement screen based on the availability of a frozen
sample of at least two invasive lesions, from which
a minimum of 3 μg of dsDNA could be extracted
(Supplementary Tables 1 and 2), the remaining tissue
samples used for this project all being formalin-fixed,
paraffin-embedded (FFPE). The project was approved
by the internal ethics committees of the two contributing
hospitals (internal numbers and dates: 1748-19/08/2010
and 2028-11/10/2012) and conducted according to the
principles of the Declaration of Helsinki.
Targeted gene screen
The exonic regions of 360 cancer-related genes (Sup-
plementary Table 3) were enriched using in-solution
RNA baits (SureSelect, Agilent, UK) and sequenced on
an Illumina HiSeq 2000 instrument at the Wellcome
Trust Sanger Institute. Samples from eight patients were
processed with an earlier version of the bait design,
lacking 46 of those 360 genes (Supplementary Tables
2 and 3). Seven hundred nanograms to one micro-
gram of DNA was fragmented to an average insert size
of 145 bp (75–300) and subjected to Illumina DNA
sequencing library preparation using the Bravo Auto-
mated Liquid Handling Platform. Individual samples
were indexed using a unique DNA barcode via six cycles
of PCR. Equimolar pools of 16 libraries were prepared
and hybridized to custom RNA baits following the Agi-
lent SureSelect protocol and sequenced on the Illumina
HiSeq devices using the 75-base pair paired-end pro-
tocol. Somatic base substitutions and small insertions
or deletions were identified by comparison with the
matched normal sample using established bioinformatic
algorithms [18,19].
All mutations identified in at least one sample from
a patient were further interrogated by deep resequenc-
ing using the Life Technologies Ion TorrentTM technol-
ogy and confirmed to be present when the frequency of
mutated reads was≥ 5%, as in ref 20. Mutations with a
frequency≥ 1% but< 5% were defined as present only
if there was at least one other sample in the same patient
reporting the same mutation with a mutant allele frac-
tion≥ 5%. In brief, samples were analysed with heavily
multiplexed primer pools, encompassing a total of 295
amplicons, designed with AmpliSeq® Designer v 3.0.1
(Life Technologies Inc, Carlsbad, CA, USA). Targeted
resequencing was performed by barcoding samples on
318TM chips and running the analyses on a PGMTM
device (Life Technologies Inc), using the Torrent Suite
pipeline and default parameters for FFPE material.
The sequencing data are available through the EBI’s
European Genome–phenome Archive under accession
number EGAD00001001041.
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Identification of oncogenic mutations
Mutations were classified in one of the following cat-
egories according to the following definition, slightly
modified from Papaemmanuil et al [21]:
(1) Oncogenic: non-synonymous substitutions or
in-frame mutations in canonical oncogenes at
recurrent hotspots; non-synonymous substitutions
recurrent in two or more confirmed samples in
COSMIC; non-synonymous substitutions recurrent
in two or more samples in our own dataset; and
nonsense, frameshifting insertions, and deletions in
known tumour suppressors;
(2) Putative oncogenic: previously unreported
non-synonymous substitutions in a known cancer
gene within ±3 amino acids of a mutation recurrent
in two or more samples in COSMIC; more than two
non-synonymous substitutions within three amino
acids of each other (mutation clusters);
(3) Possible oncogenic: non-synonymous substitutions
confirmed somatic in one sample in COSMIC;
mutations close to mutation clusters in COSMIC;
(4) Unknown significance: all remaining mutations.
For the sake of simplicity, all oncogenic, putative,
and possible oncogenic mutations are referred to as
‘oncogenic’ here.
Whole-genome sequencing
Tumour genomic DNA from frozen multifocal lesions
and matched germline DNA from eight patients were
prepared for Illumina paired-end sequencing according
to the standard protocol (Illumina Inc, San Diego, CA,
USA). Short reads were mapped back to the reference
genome (GRCh37) and discordantly mapping reads
were identified as pairs that did not match with the
expected insert size, mapped in the wrong orientation,
or mapped to different genomic regions, as previ-
ously described [22,23]. Putative rearrangements were
validated and breakpoint annotated using capillary
sequencing. Copy number alterations were assessed
by QDNAseq (version 1.0.5) [24] by first binning
the reads in non-overlapping 100 kb windows. Bins
in problematic regions were blacklisted. Read counts
were corrected for GC content and mappability using
a LOESS regression and median normalized. Raw log2
ratios were smoothed to remove outlier points using
the median absolute deviation and segmented using
the multitrack PCF algorithm as implemented in the
R package copynumber (version 1.6.0) [25]. Absolute
estimates of copy numbers were obtained using ABSO-
LUTE (version 1.0.6) [26] in ‘total’ copy number mode
and possible solutions of ploidy and cancer cell fraction
were manually reviewed as explained on the software’s
webpage. Distance measures between lesions of a given
patient were computed using a one-step minimum
event distance metric as implemented in the package
MEDICC (version 10/2014) [27]. We further compared
the copy number status for the breast cancer-specific
focal copy-number aberrations previously described in
ref 28.
Statistical analyses
Spearman’s ρwas used to assess the correlation between
allelic frequencies obtained with Illumina and Ion Tor-
rent technologies. Wilcoxon’s tests were used to test
the significance of non-zero shift for samples from two
categories and Kruskal–Wallis tests were used to test
whether samples for more than two categories had the
same distribution. Fisher’s exact tests were used for the
analysis of contingency tables. All tests rejected the null
hypothesis with a two-tailed p value of 0.05.
Additional methods are reported in the Supplemen-
tary methods.
Results
Targeted sequencing of cancer genes in MFBC
To investigate the potential genomic heterogeneity
between ductal MFBC lesions with centrally confirmed
homogeneity in grade, ER, and HER2 status, we con-
ducted targeted sequencing of cancer-related genes in
multifocal lesions from 36 patients (Table 1 and Sup-
plementary Tables 1–3). Whenever lesion size allowed,
we interrogated multiple geographically distinct sam-
ples per lesion, leading to a total of 171 investigated
tumour samples. Sequencing was carried out at a
median exonic coverage of 178×. Overall, 474 somatic
mutations were identified, corresponding to 145 and
55 unique coding non-silent somatic substitutions and
indels, respectively, across all samples (Supplementary
Table 4).
To independently confirm the presence or absence
of these mutations, we performed a second targeted
sequencing experiment at greater sequencing depth
(median coverage of 1344×) using an alternative plat-
form (Supplementary Figure 1A). We could not confirm
35 mutations (7%), due to either design/technical fail-
ures (n= 19 mutations) or the lack of remaining DNA
for four samples (n= 16 mutations). We validated 389
mutations among the remaining 439 (89%, referred to
as ‘confirmed’ in Supplementary Table 4) and observed
a strong correlation between the allelic frequencies
reported by the two sequencing technologies (ρ= 0.81,
Supplementary Figures 1B and 1C). The area under
the ROC curve of Illumina and PGM sequencing,
which can be considered as the probability to classify
as positive a randomly chosen positive observation
with the first method, had a value of 78.94% (95%
CI= 71.25–86.62%). Fifty mutations could not be
detected above the predefined cut-off despite sufficient
coverage at that specific genomic location. Of interest,
this additional sequencing step also identified the pres-
ence of 52 additional mutations in samples where the
mutation was previously undetected though present in
other sample(s) from the same patient (referred to as
‘present’ in Supplementary Table 4).
© 2015 The Authors. Pathological Society of Great Britain and Ireland. J Pathol 2015; 236: 457–466
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Table 1. Patient characteristics
Total No of patients
Age, years
<40 2
40–49 11
50–69 17
>70 6
Tumour size, cm
1–2 17
2–5 18
>5 1
No of positive nodes
None 16
1–3 16
4–9 1
>10 3
Tumour grade
G1 8
G2 7
G3 21
Molecular subtype
ER+/HER2− 26
ER−/HER2− 4
HER2+ 6
DCIS
Absent 6
Present 30
LVI
Absent 21
Present 14
Unknown 1
Inter-lesion distance*, cm
<2 10
≥2 16
Unknown 10
No of lesions
2 22
>2 14
DCIS= ductal carcinoma in situ; LVI= lymphovascular invasion.
*When there were more than two lesions, the largest inter-lesion distance was
taken into consideration for this table and for the downstream analyses.
We observed a median of three mutations (range
1–27) per patient. The number of mutations detected per
patient correlated neither with the number of lesions nor
with the number of samples sequenced (Supplementary
Figures 2A and 2B). Of note, among the 141 validated
unique mutations, 62 (44%) were identified as onco-
genic (see the Materials and methods section) and thus
susceptible to having contributed to the development of
the cancer.
Identification of inter-lesion heterogeneity
By comparing the mutations identified in the various
samples and lesions of a single patient, we arbitrarily
classified the patients into three groups: those for which
all samples from all lesions carried the same muta-
tions (11/36 patients, 31%, Figure 1); those with both
common and private mutations (13/36 patients, 36%,
Figure 2); and those with no single mutation in common
among all samples from the investigated lesions (12/36
patients, 33%, Figure 3). These groups will further
be referred to as ‘homogeneous’, ‘intermediate’, and
‘heterogeneous’, respectively. There was no significant
association between the number of samples and lesions
that were sequenced per patient and the group to
which they were categorized (Supplementary Figures
2C and 2D). In contrast, these groups were signifi-
cantly associated with the total number of mutations per
patient: patients from the homogeneous group had fewer
mutations than patients from the heterogeneous group
(median number of mutations: 2.5 and 4.5, respectively;
p= 0.030; Supplementary Figure 2E). Nevertheless,
the number of mutations per lesion between those two
groups of multifocal tumors was not significantly differ-
ent (p= 0.568). Of note, the vast majority of the homo-
geneous and intermediate cancers (9/11 and 9/13) shared
at least one oncogenic mutation, potentially representing
common and early events during MFBC carcinogenesis.
In the intermediate group, the median allelic fre-
quency of private mutations (ie those not shared by
all samples of a given patient) was lower than that
of common mutations (0.13 versus 0.26, p= 0.042
using a Wilcoxon’s signed rank test for paired data).
Although copy losses could account for this observa-
tion, we believe that the emergence of private, subclonal
alterations provides a more general and biologically
plausible explanation.
In the heterogeneous group, most cancers were char-
acterized by the presence of different oncogenic muta-
tions in the investigated lesions. In six patients, onco-
genic PIK3CAmutations were only present in one of the
lesions. A similar observation was found for oncogenic
TP53 (n= 3), GATA3 (n= 3), and PTEN (n= 2) muta-
tions. We further demonstrated that the PTEN mutation
resulted in the loss of PTEN staining by immunohisto-
chemistry only in the lesion carrying the mutation, as
exemplified for patient PD13774 in Figure 3B.
Finally, we observed a case of possible convergent
evolution for patient PD4877, with each lesion carrying
a different TP53 oncogenic mutation (all three samples
from the first lesion carried the R196* mutation, whereas
one sample from the other lesion was characterized by
the R273H variant).
Altogether, these results suggest that although multi-
focal tumours may look identical at pathological evalu-
ation, for a substantial number of patients, their lesions
differ in terms of oncogenic mutations.
Association of inter-lesion heterogeneity
with clinico-pathological variables
We further sought to investigate whether inter-lesion
heterogeneity was associated with clinical or histopatho-
logical variables, such as age at diagnosis, axillary
lymph node involvement, tumour size, molecular
subtype of the tumour based on ER and HER2 sta-
tus, histological grade, number of multifocal lesions,
largest distance between lesions, presence of in situ
component, and lymphovascular invasion. The only
association found was that of inter-lesion distance: the
lesions from patients of the heterogeneous group were
further apart from each other than those from patients
of the homogeneous group, although the p value was of
© 2015 The Authors. Pathological Society of Great Britain and Ireland. J Pathol 2015; 236: 457–466
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Figure 1. Distribution of non-silent substitutions and indels in the ‘homogeneous’ MFBC group. Heat maps representing the non-silent
exonic substitutions and indels of the homogeneous multifocal lesions (L), which have all the mutations in common between all the lesions.
Orange indicates the presence of an oncogenic mutation; grey the presence of a mutation of unknown significance; and white the absence
of the mutation. When a sample name is grey, it means that it was not initially sequenced, due to a lack of sufficient DNA, but was included
in the validation phase.
borderline significance (p= 0.072). A significant p value
was, however, reached when comparing patients whose
lesions had shared oncogenic mutations with those
who had only private oncogenic mutations (p= 0.015,
Supplementary Figure 3).
Genome-wide comparison of multifocal lesions
Targeted mutation screening underestimates the number
of common genetic alterations among samples because
it only interrogates a tiny fraction of the genome. To
investigate the clonal relationship between the lesions,
we carried out a low-coverage screen of somatic struc-
tural variation and copy number aberrations (SCNAs)
for the eight patients with available frozen material
(Figure 4, Supplementary Figure 4, and Supplementary
Tables 5–8). Two patients belonged to the homoge-
neous, three to the intermediate, and three to the het-
erogeneous group of MFBC tumours, as defined by tar-
geted sequencing. Interestingly, we observed common
rearrangements and SCNAs between the lesions for all
patients, even for those belonging to the heterogeneous
groups, implying that different lesions from the same
patient are genetically related. Nevertheless, we cannot
exclude that some of the common rearrangements might
have arisen during mammary gland development and/or
ageing. Although the numbers are too small to draw
any statistical conclusion, we further observed a higher
proportion of private rearrangements and SCNAs for
patients belonging to the heterogeneous group, suggest-
ing an early divergent parallel evolution of the lesions.
Of note, most rearrangements did not involve a known
cancer gene. Nevertheless, we observed a tandem dupli-
cation involving the oncogeneMYC in the second lesion
of patient PD4877 (Supplementary Table 5). At the
copy number level, inter-lesion differences involving
cancer-related genes were present, such as, for example,
PTEN loss in only one of the lesions of patients PD4877,
PD4878, and PD11773, and MYC amplification in one
lesion from PD11776 (Supplementary Tables 7 and 8).
Discussion
The College of American Pathologists currently con-
siders it sufficient for the immunohistochemical charac-
terization of multifocal lesions with similar grade and
histology to be based on the largest lesion [14]. Previ-
ous studies have demonstrated that despite the similarity
of pathological features, lesions might differ in some
cases in terms of ER and HER2 receptor status, poten-
tially impacting the treatment and management of these
cancers [15–17]. Here we sought to investigate more
deeply the intra-patient, inter-lesion tumour heterogene-
ity of MFBCs, and the potential clinical implications.
To this end, we used a targeted sequencing approach
that specifically focused on cancer-related genes, sim-
ilar to those currently used by several molecular cancer
profiling initiatives (reviewed in ref 29), on a series of
171 tumour samples from 36 clinically well-annotated
MFBC patients.
Our study showed that 67% (24 patients) of MFBC
lesions share all or a fraction of the identified mutations
by targeted sequencing. Most of these lesions (18/24)
also shared oncogenic variants, suggesting a common
origin in the tumour development. Surprisingly, in
one-third of the patients (12 patients), the lesions did
© 2015 The Authors. Pathological Society of Great Britain and Ireland. J Pathol 2015; 236: 457–466
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Figure 2. Distribution of non-silent substitutions and indels in the ‘intermediate’ MFBC group. Heat maps representing the non-silent
exonic substitutions and indels of the intermediate multifocal lesions, presenting both common and private mutations. The colour code,
abbreviations, and meaning of the grey colour for sample names are the same as in Figure 1. When numbers are present after the gene
symbol, it means that different mutations were observed in the same gene.
not share any mutations despite similar histopatholog-
ical features. The lesions in all but one patient actually
differed in terms of oncogenic mutations. For example,
four patients were heterogeneous in terms of oncogenic
TP53 mutations, in line with a recent observation [30].
These differences in the presence of oncogenic muta-
tions suggest that different genetic alterations might
have been causally involved in the development of the
respective lesions in a substantial proportion of MFBCs.
Although the numbers in our study are too small to
draw definitive conclusions, we did not observe any sig-
nificant associations between inter-lesion heterogeneity
and commonly used clinico-pathological features,
with the exception of the inter-lesion distance. Indeed,
MFBCs whose lesions shared oncogenic variants were
closer to each other than lesions not sharing any onco-
genic variant. This observation supports the concept
underlying the historical definition of multicentric
and multifocal tumours – namely, that lesions in close
proximity to each other aremore likely to be biologically
similar than lesions that are far apart [1].
The fact that lesions from one-third of the MFBCs
that we studied harboured distinct oncogenic mutations
may have substantial therapeutic implications in the con-
text of genotype-driven trials. Although these trials are
mainly running in the metastatic setting, most of them
allow identification of themutation(s) to be performed in
the primary tumour [29]. In the case of MFBC, the iden-
tification of the molecular targets, for example PIK3CA
and PTEN, would differ depending on the lesion inter-
rogated. Our results therefore suggest that ideally all
lesions from patients with MFBC should be evaluated,
in particular when the lesions are relatively distant from
each other.
Another question, especially in the case of heteroge-
neous MFBCs, is whether MFBC represents clonally
related outgrowths of a common ancestral cancer cell
or completely separate, coincidental cancers. This has
been a matter of debate in the literature during the
last few decades [31–34]. Our targeted sequencing
data support a common origin in at least two-thirds of
MFBCs. Our genome-wide analyses, which are limited
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Figure 3. Distribution of non-silent substitutions and indels in the ‘heterogeneous’ MFBC group. (A) Heat maps representing the non-silent
exonic substitutions and indels of the heterogeneous multifocal lesions, which have no mutation in common between the lesions. The
colour code and abbreviations are the same as in Figure 1. (B) Immunohistochemical staining illustrating the loss of PTEN at the protein
level only in the lesion of patient PD13774 carrying the PTEN mutation.
to a subset of the patients that we studied, suggest
that an even greater proportion of MFBCs, including
those without any common oncogenic mutations, are
clonally related and consequently that the lesions arise
through intra-mammary spread of the tumour cells.
The intrinsically invasive nature of the cells making up
MFBCs might explain the worse prognostic features
associated with multifocal compared with unifocal
cancers.
Since the number of molecular alterations with
potential clinical utility is rapidly growing in parallel
with the increasing number of targeted therapies, our
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Figure 4. Genome-wide alterations. Bar plots showing the distribution and the type of somatic rearrangements (A) and the percentage of
private and common (present in all investigated lesions from that patient) rearrangements (B). (C) Genome-wide Circos plots of somatic
rearrangements of the three patients classified in the ‘heterogeneous’ group. The chromosomes are represented in the outer ring. Within
the inner ring, each blue line represents a common rearrangement, whereas each green or red line represents a rearrangement private to
lesion 1 or 2, respectively. Bar plots showing the distribution (D) and the percentage of private and common (present in all investigated
lesions from that patient) SCNAs (E). (F, G) Log2-based estimate (log2 ratio) of SCNAs, represented in light red, of two of the three patients
classified as ‘heterogeneous’.
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findings suggest that molecularly characterizing only
the largest lesion is not sufficient to adequately manage
MFBCs, especially when lesions are further apart from
each other. The implications of inter-lesion differences
in terms of treatment response to various standard and
targeted therapies, as well as in terms of disease pro-
gression, deserve further investigation. Recognizing the
potential molecular heterogeneity of these cancers has
great potential clinical relevance and already represents
an important step towards the personalized treatment of
this disease.
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